BR112015024393A2 - sal de derivado de pirazoloquinolina e cristal deste - Google Patents

sal de derivado de pirazoloquinolina e cristal deste

Info

Publication number
BR112015024393A2
BR112015024393A2 BR112015024393A BR112015024393A BR112015024393A2 BR 112015024393 A2 BR112015024393 A2 BR 112015024393A2 BR 112015024393 A BR112015024393 A BR 112015024393A BR 112015024393 A BR112015024393 A BR 112015024393A BR 112015024393 A2 BR112015024393 A2 BR 112015024393A2
Authority
BR
Brazil
Prior art keywords
acid
crystal
derivative salt
salt
pyrazoloquinoline derivative
Prior art date
Application number
BR112015024393A
Other languages
English (en)
Inventor
Ozaki Shunsuke
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BR112015024393A2 publication Critical patent/BR112015024393A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

resumo patente de invenção para "sal de derivado de pirazoloquinolina e cristal deste" a presente invenção proporciona um sal de (s)-7-(2-metoxi-3,5-dimetilpiridin-4-il)-1-(tetraidrofuran-3-il)-1h-pirazolo[4,3-c]quinolin-4(5h)-ona e um ácido selecionado a partir do grupo que consiste em ácido clorídrico, ácido bromídrico, ácido sulfúrico, ácido nítrico, ácido fosfórico, ácido malônico, ácido maleico, ácido tartárico, ácido metanossulfônico, ácido benzenossulfônico e ácido toluenossulfônico; ou um cristal deste que pode ser potencialmente usado como substância farmacológica em produtos farmacêuticos.
BR112015024393A 2013-04-05 2014-04-03 sal de derivado de pirazoloquinolina e cristal deste BR112015024393A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013079639 2013-04-05
PCT/JP2014/059853 WO2014163147A1 (ja) 2013-04-05 2014-04-03 ピラゾロキノリン誘導体の塩およびその結晶

Publications (1)

Publication Number Publication Date
BR112015024393A2 true BR112015024393A2 (pt) 2017-10-24

Family

ID=51658438

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015024393A BR112015024393A2 (pt) 2013-04-05 2014-04-03 sal de derivado de pirazoloquinolina e cristal deste

Country Status (13)

Country Link
US (1) US9573947B2 (pt)
EP (1) EP2982675B1 (pt)
JP (1) JP5666755B1 (pt)
KR (1) KR101997955B1 (pt)
CN (1) CN105121440B (pt)
AU (1) AU2014250392B2 (pt)
BR (1) BR112015024393A2 (pt)
CA (1) CA2907971C (pt)
ES (1) ES2645149T3 (pt)
MX (1) MX359843B (pt)
RU (1) RU2655171C2 (pt)
SG (1) SG11201507897SA (pt)
WO (1) WO2014163147A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017090716A1 (ja) * 2015-11-26 2017-06-01 持田製薬株式会社 ピラゾール誘導体の結晶
AU2018276568A1 (en) * 2017-06-01 2019-11-07 Eisai R&D Management Co., Ltd. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
KR20200010220A (ko) * 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제
MX2019013198A (es) 2017-06-01 2020-01-20 Eisai R&D Man Co Ltd Composicion farmaceutica que comprende un inhibidor de (s)-7-(2metoxi-3,5-dimetilpiridin-4-il)-1-(tetrahidrofuran-3-il)- 1h-pirazolo[4,3-c]quinolin-4(5h)-ona (pde9).
SG10202113198TA (en) 2017-06-01 2021-12-30 Eisai R&D Man Co Ltd Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
US11530218B2 (en) 2020-01-20 2022-12-20 Incyte Corporation Spiro compounds as inhibitors of KRAS
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
AU2022367432A1 (en) 2021-10-14 2024-05-02 Incyte Corporation Quinoline compounds as inhibitors of kras

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05132484A (ja) 1991-04-26 1993-05-28 Otsuka Pharmaceut Factory Inc ピラゾロキノリン及びピラゾロナフチリジン誘導体
JP2828506B2 (ja) 1994-05-24 1998-11-25 エフ・ホフマン−ラ ロシュ アーゲー 三環式ジカルボニル誘導体
AU2003250539A1 (en) * 2002-08-07 2004-02-25 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
RU2426734C2 (ru) 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Пиразолопиридины и их аналоги
WO2005118583A1 (en) 2004-05-28 2005-12-15 Millennium Pharmaceuticals, Inc. 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors
JP2006045118A (ja) * 2004-08-04 2006-02-16 Mochida Pharmaceut Co Ltd 新規ピラゾロキノロン誘導体
CN101268073B (zh) 2005-09-15 2011-10-19 Aska制药株式会社 杂环化合物、制备方法及其用途
ES2536906T3 (es) 2006-12-13 2015-05-29 Aska Pharmaceutical Co., Ltd. Derivado de quinoxalina
NZ580904A (en) 2007-05-11 2012-02-24 Pfizer Amino-heterocyclic compounds for inhibiting pde9
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CN102341399A (zh) 2009-03-05 2012-02-01 安斯泰来制药株式会社 喹喔啉化合物
JP5542196B2 (ja) 2009-03-31 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １−複素環−１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｐｄｅ９ａモジュレーターとしてのそれらの使用
ES2583528T3 (es) * 2010-09-07 2016-09-21 Astellas Pharma Inc. Compuesto de pirazoloquinolina
JP6042060B2 (ja) 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
PT2573073E (pt) * 2011-09-26 2015-02-05 Sanofi Sa Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica
PL2769980T3 (pl) * 2011-10-07 2016-07-29 Eisai R&D Man Co Ltd Pochodna pirazolochinoliny jako inhibitory PDE9

Also Published As

Publication number Publication date
SG11201507897SA (en) 2015-11-27
CA2907971A1 (en) 2014-10-09
EP2982675B1 (en) 2017-08-16
MX359843B (es) 2018-10-12
EP2982675A1 (en) 2016-02-10
EP2982675A4 (en) 2016-08-10
AU2014250392B2 (en) 2018-03-01
JP5666755B1 (ja) 2015-02-12
KR101997955B1 (ko) 2019-07-08
WO2014163147A1 (ja) 2014-10-09
RU2015140619A (ru) 2017-05-11
RU2655171C2 (ru) 2018-05-24
KR20150138203A (ko) 2015-12-09
AU2014250392A1 (en) 2015-10-15
CN105121440B (zh) 2017-05-24
RU2015140619A3 (pt) 2018-03-26
US9573947B2 (en) 2017-02-21
JPWO2014163147A1 (ja) 2017-02-16
CA2907971C (en) 2020-12-29
CN105121440A (zh) 2015-12-02
US20160046623A1 (en) 2016-02-18
ES2645149T3 (es) 2017-12-04
MX2015013620A (es) 2016-02-25

Similar Documents

Publication Publication Date Title
BR112015024393A2 (pt) sal de derivado de pirazoloquinolina e cristal deste
CL2014000821A1 (es) Compuestos derivados de 1h-pirazolo[4,3-c]quinolin-4(5h)-ona, inhibidores de la fosfodiestera 9 (pde9); composicion farmaceutica que los comprende; y agente para mejorar la alteracion cognitiva en la enfermedad de alzheimer.
CY1119588T1 (el) Εκλεκτικοι αναστολεις pi3κ δελτα
BR112016024626A2 (pt) 1h-pirrolo[2,3-c]piridin-7(6h)-onas e pirazolo[3,4-c]piridin-7(6h)-onas como inibidores de proteínas bet
BR112014018528A8 (pt) Derivados de pirido [2,3] pirimidina 2-amino, 6-fenil substituídos úteis como inibidores de raf quinase
BR112013024717A2 (pt) anticorpo isolado, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, método de tratar um indivíduo que tem câncer e método de inibir proliferação celular em um indivíduo
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
IL241573B (en) Transformed histories of [2h]imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidine-4[5h]-one, a pharmaceutical preparation containing them and their use as drugs
PH12015500073A1 (en) Macrocyclic purines for the treatment of viral infections
BR112013019354A2 (pt) derivados de (1,2,4)triazolo[4,3-a]quinoxalina como inibidores de fosfodiesterases
DK3489238T3 (da) Farmaceutiske sammensætninger af 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-on- og [1,2,4]triazolo[1,5-c]pteridin-5(6h)-on-derivater som pde1-inhibitorer til behandling af for eksempel neurologiske lidelser
CR20180199A (es) Acetamida tienotriazolodiazepinas y usos de las mismas
CO2018013803A2 (es) 1h-pirazolo[4,3-b]piridinas como inhibidores de pde1
CR20140481A (es) Compuestos triazolo como inhibidores de pde10
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
MX367425B (es) Derivados de 4-carboxamido-isoindolinona como inhibidores selectivos de parp-1.
BR112019016839A2 (pt) tratamentos de combinação que compreendem a administração de 1h-pirazolo[4,3-b] piridinas
MX2014006015A (es) Derivados de 3-fenil-isoquinolin-1 (2h) -ona como inhibidores de parp-1.
ECSP13012599A (es) Hidrato de tartrato DE 1-{(2S)-2-amino-4-[2,4-bis(trifluorometil)-5,8-di-hidropirido[3,4-d]pirimidin-7(6H)-il]-4-oxobutil}-5,5-difluoro-piperidin-2-ona
TN2015000045A1 (en) Tris(hetero)arylpyrazoles and use thereof
AR122753A2 (es) Inhibidores selectivos de proteínas cinasas delta pi3k, composiciones farmacéuticas, usos, y métodos de tratamiento y/o prevención de las enfermedades o trastornos mediados por cinasas
TH182466B (th) สารกลุ่ม 1เอช-ไพร์โรโล[2,3-ซี]ไพริดิน-7(6เอช)-โอน และไพราโซโล[3,4-ซี] ไพริดิน-7(6เอช)-โอน ที่เป็นตัวยับยั้งของโปรตีน bet
MA38950A1 (fr) Thiénouracile-carboxamides cycliques et utilisation associée
TH1501001335A (th) กระบวนการที่ปรับปรุงแล้วสำหรับการเตรียมของ 2-อะมิโน-5,8-ไดเมธอกซิ[1,2,4]ไทรอะโซโล[1,5-c]ไพริมิดีนจาก 4-อะมิโน-2,5-ไดเมธอกซิไพริมิดีน

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]